Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.21 USD
+0.09 (4.25%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $2.24 +0.03 (1.36%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.21 USD
+0.09 (4.25%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $2.24 +0.03 (1.36%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
Earnings Preview: Esperion Therapeutics (ESPR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Esperion Therapeutics (ESPR) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.
Esperion Therapeutics (ESPR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -68.27% and -60.89%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Is Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -3.46% and -49.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More
by Kinjel Shah
Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
by Zacks Equity Research
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
Why Is Esperion Therapeutics (ESPR) Up 17.5% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.78% and 4.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Esperion Therapeutics (ESPR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) Up 12.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.
Esperion Therapeutics (ESPR) Beats Q2 Earnings Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 102.82% and -0.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Is Esperion Therapeutics (ESPR) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy
by Zacks Equity Research
Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging first-quarter results. The company records product revenues for the first time during the quarter.
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 9.55% and 91.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Tilray (TLRY) in Focus: Stock Moves 9.6% Higher
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Esperion's Cholesterol Drugs Receive Approval in Europe
by Zacks Equity Research
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 16.61% and 1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?